Latest AI Articles:

The rise of AI industrial robotics experienced record double-digit expansion in various countries in 2014 and 2015, but such large scale segments i.e. 'industrial' versus 'medical' or 'military', were more or less one amalgam of parts a couple of decades ago. Examples of medical and military applications can be found in our updated machine learning in robotics guide. There was a time before the early 1980s when it was possible for AI researchers to keep up with all that was going on in the AI and the robotics industry as a whole, but it seems the tides had changed by 1982.

Episode Summary: Getting beyond the marketing and jargon on the home pages of AI companies and figuring out what's actually happening, what results are being driven in business, is part of our job at Emerj. Shaking those answers out of founders is not always easy, but we didn't have to do much shaking with Yohai Sabag, chief data scientist for Optimove, a marketing AI and automation company in Israel. In this episode, he speaks about what humans are needed for in the optimization process, and what facets can be automated or distributed to a machine. Sabag gives an excellent walk-through of how marketers can use the "human-machine feedback loop" for artificial intelligence in marketing optimization at scale.

When it comes to effectiveness of machine learning, more data almost always yields better results—and the healthcare sector is sitting on a data goldmine. McKinsey estimates that big data and machine learning in pharma and medicine could generate a value of up to $100B annually, based on better decision-making, optimized innovation, improved efficiency of research/clinical trials, and new tool creation for physicians, consumers, insurers, and regulators.
Where does all this data come from? If we could look at labeled data streams, we might see research and development (R&D); physicians and clinics; patients; caregivers; etc. The array of (at present) disparate origins is part of the issue in synchronizing this information and using it to improve healthcare infrastructure and treatments. Hence, the present-day core issue at the intersection of machine learning and healthcare: finding ways to effectively collect and use lots of different types of data for better analysis, prevention, and treatment of individuals.
Burgeoning applications of ML in pharma and medicine are glimmers of a potential future in which synchronicity of data, analysis, and innovation are an everyday reality.
At Emerj, the AI Research and Advisory Company, we research how AI is impacting the pharmaceutical industry as part of our AI Opportunity Landscape service. Global pharma companies use AI Opportunity Landscapes to find out where AI fits at their company and which AI applications are driving value in the industry.
In this article, we use insights from our research to provide a breakdown of several of the pioneering applications of AI in pharma and areas for continued innovation.

Episode Summary: You might be aware that some of the articles online about sports or financial performance of companies are article written by machines; this machine learning-based technology is the burgeoning field of natural language generation (NLG), which aims to create written content as humans would—in context— but at greater speed and scale. Yseop is one such enterprise software company, whose product suite turns data into written insight, explanations, and narrative. In this episode we interview Yseop's Vice President Matthieu Rauscher, who talks about the fundamentals of NLG in business, and what conditions need to be in place in order to drive business objectives. Rauscher also addresses the difference between discover-oriented machine learning (ML) and production-level ML, and why different industries might be drawn to one over the other.

More data, less problems?
How AI is transforming the financial marketplace and operations from the inside out.
AI got a head-start in the information-rich financial industry over two decades ago, though the applications of today—robo-advisors and algorithmic traders, for example—are far more autonomous and omnipresent, accelerated in large by the increasing availability of data and advanced analytics technologies. The "prestige" associated with the use of AI and ML technologies in finance is reflected in initiatives like The AI Financial Summit, an invite-only conference that gathers C-level execs from across the financial industry sector and puts them in a room with AI experts and service providers. But a company doesn't necessarily need to be invited to a closed conference in order to apply or learn from emerging technologies in the industry.

Technology Provider: Optimove

User Company: Adore Me

Industry: Consumer Retail

Episode Summary: There is, in fact, a dark side to AI. Although we’re certainly not at the point where we need to fear terminators, it’s certainly been leveraged toward malicious aims in a business context. In data security, tremendous venture dollars are going into preventing fraud and theft, but this same brand of technology is also being use by the “bad guys” to try and steal that information and break into machine learning-protected systems. In this episode, I speak with Justin Fier, director of cyber intelligence at Darktrace, who speaks about the malicious uses of AI and how companies like Darktrace have been forced to fight these “AI assailants.” Fier provides valuable insights into the role of unsupervised learning, an addition to the full list of AI for data security applications that we've covered in the past.
 

Though yet to become a standard in schools, artificial intelligence in education has been taught since AI's uptick in the 1980s. In many ways, the two seem made for each other. We use education as a means to develop minds capable of expanding and leveraging the knowledge pool, while AI provides tools for developing a more accurate and detailed picture of how the human mind works.

Episode Summary: Most of our recent investor interviews have been Bay area investors, like Accenture and Canvas, and we don't usually get to speak with investors overseas, particularly in Asia. This week, however, we interviewed Tak Lo, a partner with Zeroth.ai, an accelerator program and cohort investing firm based in Hong Kong and focused on startup artificial intelligence (AI) and machine learning (ML) companies. Lo speaks about when he saw AI take off in Hong Kong and the differences in that rise compared to the U.S. He also gives valuable insight on consumer differences in how the two populations interact with technology (a topic echoed in an earlier Emerj interview with Baidu's Adam Coates), and how these differences in the Asian market drive different business opportunities in Hong Kong than in the U.S.

There is a certain level of stigma that exists around using machine learning and location data in business applications, understandably due to risks inherent in exploitation of individual privacy. But if we look under the hood of society's daily web of interactions, we see that the location information economy—from GPS to radio signal based-triangulation to geo-tagged images and beyond—is now almost ubiquitous, from the moment we track our morning commute to the end-of-day search for healthy and convenient take-out for dinner.